

NRA-0160

Catalog No: tcsc6782



Available Sizes

Size: 1mg

Size: 5mg

Size: 10mg

Size: 20mg



Specifications

CAS No:

204718-47-8

Formula:

$C_{24}H_{23}F_2N_3OS$

Pathway:

GPCR/G Protein;Neuronal Signaling;GPCR/G Protein;Neuronal Signaling;GPCR/G Protein

Target:

Dopamine Receptor;Dopamine Receptor;Adrenergic Receptor;5-HT Receptor;5-HT Receptor

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Observed Molecular Weight:

439.52


Product Description

NRA-0160 is a selective **dopamine D4 receptor** antagonist, with a **K_i** value of 0.48 nM and with negligible affinity for **dopamine D2 receptor**

(K_i : >10000 nM), **D3 receptor** (K_i : 39 nM), rat **5-HT2A receptor** (K_i : 180 nM) and rat **α 1 adrenoceptor** (K_i : 237 nM).

IC50 & Target: K_i : 0.48 nM (D4 receptor), 39 nM (D3 receptor), 180 nM (Rat 5-HT2A receptor), 237 nM (Rat α 1 adrenoceptor)^[2]

In Vivo: NRA0160 (0.1, 1, or 3 mg/kg, i.p.) has no effect on PCP-induced hyperlocomotion, stereotypy or ataxia in SD rats. NRA0160, at any dose, does not reduce cumulated counts of locomotion and cumulated scores of stereotypy emerging, and has no effect on extracellular glutamate levels and locomotor activity emerged after saline injection^[1]. NRA0160 dose-dependently and significantly reverses the effects of MAP on both A9 and A10 dopamine neurons. NRA0160 is slightly more potent in reversing the effects of MAP on A10 (ED_{50} = 1.0 mg/kg) than on A9 dopamine neurons (ED_{50} = 1.3 mg/kg). NRA0160 reverses the effect of APO on both A9 and A10 dopamine neurons. ED_{50} values for the effects of NRA0160 on APO-induced inhibition of A9 and A10 dopamine neurons are 1.3 mg/kg and 0.5 mg/kg, respectively^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!